NeuroOne expands ATM capacity to $13.4M
NeuroOne Medical Technologies Corporation supplements its prior prospectuses to increase the amount of securities it may sell under its at‑the‑market sales agreement with JonesTrading to $13,400,000.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
NeuroOne Medical Technologies Corporation supplements its prior prospectuses to increase the amount of securities it may sell under its at‑the‑market sales agreement with JonesTrading to $13,400,000. The Sales Agreement, dated December 21, 2022, authorizes sales of common stock through Jones as sales agent in "at the market offerings." The supplement states the company previously sold approximately $8,359,586 under the Sales Agreement and that the aggregate market value of outstanding common stock held by non‑affiliates was $41.48 million, calculated using 8,117,474 non‑affiliate shares and a price of $5.11 per share as of April 22, 2026.
Insights
Supplement increases ATM capacity to allow further at‑market sales.
The supplement amends prior prospectus supplements to increase the amount eligible for sale under the Sales Agreement to $13,400,000. It references the Capital on Demand™ Sales Agreement with JonesTrading dated December 21, 2022.
Cash‑flow treatment is issuer proceeds from at‑the‑market sales; the timing and volume of actual sales depend on future executions under the agreement. Subsequent filings will report specific sales amounts and methods when they occur.
Provides an additional $13.4M of at‑the‑market capacity, extending financing flexibility.
The company reports $8,359,586 previously sold under the Sales Agreement and $358,986 sold in the 12 months prior to this supplement. The supplement clarifies available registration capacity rather than a committed draw.
Market activity will depend on execution decisions; watch subsequent Form 8‑K or prospectus supplements for actual shares sold and proceeds received.
Key Figures
Key Terms
at‑the‑market offerings (ATM) financial
Capital on Demand™ Sales Agreement financial
General Instruction I.B.6 of Form S‑3 regulatory
JonesTrading Institutional Services LLC financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did NeuroOne (NMTC) file in this prospectus supplement?
How much has NeuroOne sold under the Sales Agreement so far?
Will NeuroOne receive proceeds from these sales (NMTC)?
What market values does the supplement disclose for NeuroOne (NMTC)?
Who acts as sales agent for NeuroOne's ATM program?
AI-generated analysis. How Rhea-AI works. Not financial advice.
Filed pursuant to Rule 424(b)(5)
Registration No. 333-279871
Prospectus Supplement
(To the Prospectus Supplements dated April 3, 2025, August 16, 2024 and August 15, 2025)
(To the Prospectus dated August 16, 2024)
NeuroOne Medical Technologies Corporation
$13,400,000
Common Stock
This prospectus supplement supplements the prospectus supplements dated August 16, 2024, April 3, 2025 and August 15, 2025 (the “Prior ATM Prospectus Supplement”), to the prospectus dated August 16, 2024 (the “Base Prospectus” and, together with the Prior ATM Prospectus Supplement, the “Prior Prospectus”), relating to the offer and sale of shares of our common stock, par value $0.001 per share, through JonesTrading Institutional Services LLC (“Jones”), as sales agent, in “at the market offerings” (as defined in Rule 415 promulgated under the Securities Act of 1933, as amended) pursuant to a Capital on Demand™ Sales Agreement (the “Sales Agreement”), dated December 21, 2022, that we entered into with Jones. As of the date hereof, we have sold an aggregate of approximately $8,359,586 pursuant to the Sales Agreement. We are filing this prospectus supplement to supplement the Prior Prospectus to increase the amount of shares registered that we are eligible to sell on or after the date hereof pursuant to the Sales Agreement to $13,400,000.
This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference to the Prior Prospectus in all respects, except to the extent that the information presented herein supersedes the information contained in the Prior Prospectus. This prospectus supplement is not complete without, and may only be delivered or used in connection with, the Prior Prospectus, including any amendments or supplements thereto.
Our common stock is listed on The Nasdaq Capital Market, or Nasdaq, under the symbol “NMTC.” On June 11, 2026, the last reported sale price of our common stock on Nasdaq was $3.24 per share.
The aggregate market value of our outstanding common stock held by non-affiliates pursuant to General Instruction I.B.6 of Form S-3 was approximately $41.48 million, which was calculated based on 8,117,474 shares of our outstanding common stock held by non-affiliates and a price of $5.11 per share, which was the price at which our common stock was last sold on the Nasdaq Capital Market on April 22, 2026. During the 12 calendar months prior to and including the date of this prospectus supplement, we have sold $358,986 securities pursuant to General Instruction I.B.6 of Form S-3.
Investing in our securities involves a high degree of risk. See “Risk Factors” in the Original Prospectus and documents incorporated therein by reference for a discussion of such risk factors, which factors should be read carefully in connection with an investment in our securities.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.
Prospectus supplement dated, June 12, 2026